Product Description
Mechanisms of Action: LXR Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ralexar Therapeutics, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03859986 |
ALX-101-ATOP-204 | P2 |
Unknown status |
Dermatitis, Atopic |
2020-01-01 |
2021-11-02 |
Primary Endpoints |
|
NCT03175354 |
ALX-101-ATOP-202 | P2 |
Completed |
Dermatitis, Atopic |
2018-06-29 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|